Enterprise Value
44.97M
Cash
16.69M
Avg Qtr Burn
-5.184M
Short % of Float
0.60%
Insider Ownership
11.62%
Institutional Own.
56.56%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
AVTX-803 (CERC-803) Details Leukocyte Adhesion Deficiency Type II | Phase 3 Data readout | |
AVTX-002 (CERC-002) Details Asthma | Phase 2 Data readout | |
AVTX-002 (CERC-002) Details COVID-19 | Phase 2 Update | |
AVTX-007 (CERC-007) Details Adult Onset Still's Disease | Phase 1b Update | |
AVTX-002 (CERC-002) Details Crohns disease | Phase 1b Update | |
AVTX-006 (CERC-006) Details Lymphatic malformations | Failed Discontinued | |
AVTX-801 (CERC-801) Details Metabolic disorder, Rare genetic disease | Failed Discontinued | |
AVTX-802 (CERC-802) Details Metabolic disorder, Rare genetic disease | Failed Discontinued |